While Dexcom (NASDAQ: DXCM), Abbott (NYSE: MDT), Medtronic (NYSE: MDT) and a host of others battle it out in the expanding CGM space many investors are looking beyond diabetes as growth area for CGM. Although CGM usage continues to expand with patients with diabetes already investors are looking at other applications outside of diabetes. These investors see big dollars should patients who do not have diabetes begin to use this technology.
The area outside of diabetes that garners the most attention is using CGM as a weight loss tool. Needless to say, should it be proven that CGM usage helps . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.